Now Sundy is moving on.
On Tuesday, he left Gilead to become the CMO of Pandion Therapeutics, a Boston biotech building “bifunctional” antibodies for inflammatory diseases. It was the technology that attracted him, Sundy said. The company was developing ways to not treat immune conditions across the entire body. Instead, they were building tethers to link immune-modulating drugs to specific organs.